The European Union (EU) policy for healthcare requires the establishment of a system of European Reference Networks, union-wide information databases, and registries for rare diseases (RDs) based on shared criteria. In pursuing its goals, the ‘Building Consensus and Synergies for the EU Registration of RD Patients in Europe' (EPIRARE) project convened a meeting with experts of the competent health authorities to discuss the role of national institutional RD patient registries in supporting EU patient registration and the room for international cooperation. With this aim, this paper comparatively analyses the current situation of national institutional RD registries in the EU.

Keywords:
Epidemiology, EPIRARE, Public health, Rare diseases, Registries
1.
EPIRARE: ‘Building Consensus and Synergies for the EU Registration of RD Patients in Europe'. www.epirare.eu.
2.
Vittozzi L, Gainotti S, Mollo E, Donati C, Taruscio D: A model for the European platform for rare disease registries. Public Health Genomics 2013;16:299-304.
3.
Taruscio D, Mollo E, Gainotti S, Posada M, Bianchi F, Vittozzi L: The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Arch Public Health, in press.
4.
EPIRARE Workshop on National Registries of RD, National Institute of Health. Rome, March 2014. http://www.epirare.eu/_meet/20140304.html.
5.
Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official Journal of the European Union (2009/C 151/02). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF.
6.
The Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on cross-border healthcare. http://europa.eu/legislation_summaries/employment_and_social_policy/social_protection/sp0002_en.htm.
7.
Landais P, Messiaen C, Rath A, Le Mignot L, Dufour E, Ben Said M, Jais JP, Toubiana L, Baujat G, Bourdon-Lanoy E, Gérard-Blanluet M, Bodemer C, Salomon R, Aymé S, Le Merrer M, Verloes A: CEMARA task force: CEMARA an information system for rare diseases. Stud Health Technol Inform 2010;160:481-485.
8.
European Commission: Supporting rare diseases registries and providing a European Platform for rare diseases registration. http://ec.europa.eu/health/rare_diseases/policy/registries/index_en.htm.
10.
International Rare Disease Research Consortium. http://www.irdirc.org/.
11.
Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P: A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc, in press.
12.
Johnson SB, Whitney G, McAuliffe M, Wang H, McCreedy E, Rozenblit L, Evans CC: Using global unique identifiers to link autism collections. J Am Med Inform Assoc 2010;17:689-695.
13.
Proposal for a Regulation of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation). 2012. http://ec.europa.eu/justice/data-protection/document/review2012/com_2012_11_en.pdf.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.